Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?

@article{Miguel2015FebrileNI,
  title={Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?},
  author={Is{\'a}lia Miguel and Patr{\'i}cia Winckler and Monica Sousa and Catarina Cardoso and Ant{\'o}nio Baldaia Moreira and Miguel Brito},
  journal={Breast disease},
  year={2015},
  volume={35 3},
  pages={
          167-71
        }
}
BACKGROUND Breast cancer clinical trials prove better outcomes for anthracycline-taxane regimes albeit of a higher hematologic toxicity. Original trials may under-estimate febrile neutropenia (FN) event rates. OBJECTIVE To describe the occurrence of FN events related to FEC-D for breast cancer treatment in the real-life setting. METHODS Retrospective analysis of 189 patients with non-metastatic breast cancer consecutively treated with FEC-D (3 cycles of 5-FU, Epirubicin and Cyclophosphamide… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS